ASX Health Stocks: Another Aussie biotech gets attention in the US with a pending patent
Health & Biotech
Health & Biotech
Link copied to
Cell therapeutics specialist, Cynata Therapeutics (ASX:CYP), has just received a Notice of Allowance from the United States Patent and Trademark Office (USPTO).
The notice relates to a patent application covering the use of Cymerus mesenchymal stem cell (MSC) technology in treating asthma and allergic airways disease (AAD).
The patent, entitled “Method for Treating Allergic Airways Disease (AAD)/Asthma”, is wholly owned by Cynata.
Cymerus generates cell-based products from intermediate cells, known as mesenchymoangioblasts (MCAs), which in turn are derived from induced pluripotent stem cells (iPSCs).
It is said to addresses a critical shortcoming in existing methods of production of MSCs for therapeutic use, which is the ability to achieve economic manufacture at commercial scale without requiring multiple donors.
The inventors of Cymerus are Professor Chrishan Samuel and Dr Simon Royce, both research fellows at Monash University.
“This new milestone builds on our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2038 and beyond, particularly in the field of diseases of the lungs,” said Dr Ross Macdonald, Cynata’s CEO.
Genomics specialist, Genetic Technologies (ASX:GTG), has completed the acquisition of AffinityDNA, as first announced in May.
GTG believes that AffinityDNA is a strategic acquisition that could strengthen the direct-to-consumer channel for GTG.
It could also provide additional platform for growth in the multibillion-dollar consumer genomics market, leveraging AffinityDNA’s well-established marketplace worldwide, including in the US, UK, and Europe.
The acquisition now expands GTG’s portfolio of tests to 51 tests in 14 categories across more than 40 countries.
The three brands GTG now owns – geneType, EasyDNA and AffinityDNA – are expected to anchor revenues for its growth strategy.
Meanwhile, dental centres network, Pacific Smiles (ASX:PSQ), reported YTD patient fees of $226.4m, a decline of 5.7% year on year.
PSQ now expects its unaudited underlying EBITDA, excluding the impact of AASB16 Leases, will be approximately $11.3 million for FY22.
This result excludes the one-off impact of closing its Lismore clinic, which is immaterial, taking into account insurance recoveries.